SCHEMBL2866034

SCHEMBL2866034

CC(C)CN(C(=O)Oc1ccc(-c2nn[nH]n2)cc1)c1ccc2nc(S)sc2c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.44
ITK Q08881 1/20 0.39
XDH P47989 4/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.36
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
IDO1 P14902 1/20 0.35
LMNA P02545 1/20 0.35
GRM2 Q14416 2/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP2C8 P10632 1/20 0.34
LTB4R2 Q9NPC1 1/20 0.34
MAP3K8 P41279 1/20 0.34
MAP2K1 Q02750 1/20 0.34
CYP19A1 P11511 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2858377 0.87 ITK (0.41) MCL1ITKXDHALDH1A1TP53
SCHEMBL2867200 0.85 TMPRSS15 (0.42) MCL1ITKPTGDR2HSD17B10CYP2C9
SCHEMBL2856702 0.85 PTGDR2 (0.41) ITKPTGDR2CYP2C9CYP2C19CYP2C8
SCHEMBL2859794 0.85 IDO1 (0.42) MCL1XDHIDO1HSD17B10CYP2C9
SCHEMBL2866243 0.84 PDE3B (0.39) ITKPTGDR2GRM2HSD17B10CYP2C9
SCHEMBL3409617 0.84 MCL1 (0.41) MCL1XDHALDH1A1TP53LMNA
SCHEMBL2863746 0.83 EPHX2 (0.40) ALDH1A1
SCHEMBL2866853 0.82 MAPT (0.36)
SCHEMBL2861331 0.81 MAPT (0.43)
SCHEMBL2859668 0.81 GSK3B (0.37) ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370260-B1 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-11-24 EP claimed
US-7709510-B2 Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-05-04 US claimed
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-05-13 US claimed
EP-1370260-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP claimed
WO-2002066035-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators ME1, ME3, ME2 MCL1 1061/4885ITK 2481/4885XDH 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.